Furthermore, UALCAN analysis indicated that the mRNA expression levels of TRIP13 were significantly higher in BC patients than in healthy controls using sub‐group analysis based on clinical stage, pathological features, menopause status, lymph node stage and ethnicity analysis (Figure 2). This evidence concerns the gene TRIP13 and breast cancer.